Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Journal: The lancet. Diabetes & endocrinology
Published: February 04, 2021
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma.
Journal: Cancers
Published: July 07, 2020
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
Journal: NPJ breast cancer
Published: April 17, 2020
Administration of a novel high affinity PICK1 PDZ domain inhibitor attenuates cocaine seeking in rats.
Journal: Neuropharmacology
Published: September 06, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Journal: Cancer
Published: June 05, 2018
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 12, 2018
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.
Journal: The Lancet. Oncology
Published: November 01, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Journal: The Lancet. Oncology
Published: April 11, 2017
Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects.
Journal: Clinical drug investigation
Published: August 23, 2014
Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
Journal: Clinical pharmacology in drug development
Published: June 13, 2014
Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Journal: Cancer chemotherapy and pharmacology
Published: May 15, 2014
Last Updated: 09/26/2026